

Turn around time (TAT):
7 Days




CHROMOSOMAL MICRO ARRAY



What is a Chromosomal Microarray (CMA)?

- ◆ It is a microchip-based testing platform that allows automated analysis of many pieces of DNA at once.
- ◆ CMA analysis offers the capacity to examine the whole human genome in a single chip with high resolution. It offers unparalleled screening for deletions, duplications, loss of heterozygosity for all chromosomes.
- ◆ CMA chips use probes that hybridize with specific Chromosomal regions to detect copy number variations (CNV).
- ◆ CMA offers a combination of CNV and single Nucleotide Polymorphisms (SNP)



What are the advantages of CMA in clinical practice?

Compared to Karyotyping, CMAs offer the following advantages:

- ◆ Higher resolution
- ◆ Nearly double the diagnostic yield
- ◆ Multiplexing/throughput is possible
- ◆ Detection of maternal cell contamination
- ◆ Detection of uniparental disomy



← Fig:1 Karyotype View



Which all conditions can CMA detect?


Conditions characterized by mental retardation such as:

- Angelman Syndrome
- Wolf-Hirschhorn Syndrome
- Williams Syndrome
- DiGeorge Syndrome
- Prader-Willi Syndrome
- Accurate identification of a number of chromosome disorders early in pregnancy, including virtually all known microdeletion and microduplication syndromes.
- Detection of a variety of gains or losses towards the ends (telomeres) of the chromosomes, the important causes of many developmental disability syndromes.

How the test is done?

A blood sample is preferred for microarray analysis. Sometimes spit (saliva), tissue sample, POC, Amniotic Fluid and chorionic villi may be used. This test compares the patient's sample to a normal control sample to find very small missing or extra chromosome pieces that cannot be seen under a microscope. The test does not show structural changes in chromosomes.

Clinical Genetic Testing: Patients with unexplained DD, MR, MCA, ASD*



* Excludes patients with recognizable syndrome (e.g. Down syndrome), family history of a chromosomal rearrangement or multiple miscarriages

* International standard cytogenetic array (ISCA) consortium

** David T. Miller, Margaret P. Adam, Swaroop Aradhya, et al. "Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies" The American Journal of Human Genetics, Volume 86, Issue 5, Pages 749-764 (May 2010)

Test sample requirements

- Blood (3-5 ml in EDTA tubes)
- Amniotic Fluid (AF)
- Chorionic Villi (CVS)
- Product of Conception (POC) or (minimum 200mg of POC)

Required forms:

- Relevant clinical information including all the clinical presentations and symptoms
- Test request form